NCT06751602
Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
Enrolling by Invitation
PHASE2Ages 18–75InterventionalPreventionThe Methodist Hospital Research InstituteInvestigator-initiated
~40 participants
Updated 2025-11-12 on ClinicalTrials.gov
What's tested:Belumosudil 200 mg QDPlacebo
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Difference in Severe Treatment-Emergent Adverse Events within 12 Months
Measured over Time of first dose to 12 months after first dose (study drug/placebo)
Conditions
Where it's being run
1 sites across 1 statesTexas1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Receiving a first or second kidney, except those whose first kidney transplant was lost during year 1 due to rejection or recurrent disease
Male or female, aged ≥18 to ≤75
Women of child bearing potential who have a negative serum pregnancy test prior to treatment
Women of child bearing potential (including perimenopausal women who have had a menstrual period within the previous 1 year) who agree to use 2 forms of effective birth control regimen (at least one of which is a barrier method) throughout the study period and for 6 weeks following the end of the study or the last dose of mycophenolic acid, whichever comes first.
Sexually active male patients who agree to use effective contraception during treatment of the male patient and for at least 90 days after cessation of treatment with mycophenolic acid.
Panel of reactive antibodies (PRA) \<80% based on the most recent PRA results that are closest to the date of transplant
Able to take oral medication
Agreement to adhere to Lifestyle Considerations throughout study duration (refraining from consumption of grapefruit or grapefruit juice; stopping anticoagulation therapy one week prior through one week post-kidney biopsy procedure; agree to follow FDA guidelines regarding contraception while using mycophenolic acid)
Exclusion
Transplantation of any organ other than kidney
Living donor kidney recipients having a 6-antigen match with their donor or a 0-antigen mismatch
Planned use of non-calcineurin inhibitor immunosuppression maintenance therapy (eg, belatacept)
Patients with primary focal segmental glomerulosclerosis
Recipients of en-bloc kidneys
Patients who have received or are expected to receive alemtuzumab
Presence of any donor-specific antibody observed during the current or historical crossmatch assessment
Presence of primary (or familial) dyslipidemia
Presence of an increased QTc interval \> 480 ms on screening ECG, a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure.
Patients with a history of CABG, cardiac stent placement, or MI within 1 year prior to enrollment
Patients taking high intensity statin therapy (ie, atorvastatin 40 or 80mg, rosuvastatin 20-40mg)
Diagnosed with severe liver disease, including abnormal liver enzymes greater than 3 times the upper limit of normal or total bilirubin greater than 1.5 times the upper limit of normal.
Diagnosed with any past or present malignancies except squamous or basal cell carcinoma of the skin excised prior to randomization.
Diagnosed with active acute or chronic infection, or febrile illness, including absolute neutrophil count less than 1.5 K/µL that, in the Principal Investigator's opinion, would impact the patient's safety or any assessments of this study
Diagnosed with a genetic disease that leads to excessive bleeding (eg, hemophilia A or factor VIII deficiency, hemophilia B or factor IX deficiency, and von Willebrand disease), genetic or acquired disease that leads to excessive clotting (eg, anti-phospholipid syndrome, factor V Leiden thrombophilia, factor II mutation), or a medical condition requiring uninterrupted long-term systemic anticoagulation after transplantation, which would interfere with obtaining biopsies.
Patient with platelet count less than 50 K/µL.
Ever diagnosed with Post-Transplant Lymphoproliferative Disorder (PTLD) if a previous kidney transplant was received
Use of any investigational drug during the 4 weeks prior to enrolling in this study
Women of child bearing potential who are breastfeeding
Women of childbearing potential not practicing reliable methods of contraception. Reliable methods for contraception include surgical sterilization (hysterectomy, bilateral tubal ligation), double-barrier method (such as condom and diaphragm). To be considered as post-menopausal and not of childbearing potential, female participants must have experienced 12 consecutive months of amenorrhea.
Men who are sexually active but do not practice reliable birth control.
Known allergic reactions to components of REZUROCK®, specifically belumosudil mesylate, microcrystalline cellulose, hypromellose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide or yellow iron oxide.
Any participant whose surgeon expects they will not perform a baseline biopsy pre- or post-reperfusion of the transplanted organ
Presence of any medical or psychosocial condition, which the investigator believes, would hinder adherence to the study requirements
What this trial measures
- Difference in Severe Treatment-Emergent Adverse Events within 12 MonthsTime of first dose to 12 months after first dose (study drug/placebo)
The difference in the proportion of cumulative treatment-emergent adverse events determined to be ≥ grade 3 severity that occur during 12 months from the first dose of belumosudil compared to the placebo group